Skip to content

Study · Not a test of the peptide alone · 2009

1 result

Plasmon-waveguide resonance studies of ligand binding to integral proteins in membrane fragments derived from bacterial and mammalian cells.

Salamon Z, Fitch J, Cai M, Tumati S, Navratilova E, Tollin G

Analytical biochemistry19 Jan 2009Cited by 7 (Europe PMC)

PMID19454250 (opens in a new tab)PMCIDPMC2783692 (opens in a new tab)DOI10.1016/j.ab.2009.01.019 (opens in a new tab)PepBankPUB-19454250
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01LabNot a test of Melanotan II aloneIn vitro (cell-free)Activity measurement

    Plasmon-waveguide resonance detected and characterized binding of melanotan II to MC4 receptors in membrane fragments from transfected HEK cells.

    In plain wordsIn lab tests, a new method measured melanotan II binding to MC4 receptors in cell membrane fragments.

    Peptide
    Melanotan II
    Outcome
    Not applicableMelanotan-II binding to MC4 receptor in membrane fragments by plasmon-waveguide resonance
    Study

    humann: not reported in source

    MC4 receptor-transfected HEK cell membrane fragments on a PWR spectrometer
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Binding of ligands (cytochrome c(2) for the chromatophores, the peptide agonists DAMGO and melanotan-II that are specific for the mu-opioid and MC4 receptors, and two nonpeptide agonists that are specific for the CB1 receptor) to these membrane fragments has been observed and characterized with high…

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.